SML3905

FerroLOXIN-2

≥98% (HPLC)

• Synonym(e): N-(3-Bromo-4-(trifluoromethyl)benzyl)-1-(3-fluorophenyl)-4-phenyl-1H-imidazol-2-amine trifluoroacetate, N-[[3-Bromo-4-(trifluoromethyl)phenyl]methyl]-1-(3-fluorophenyl)-4-phenyl-1H-imidazol-2-amine trifluoroacetate
• Empirische Formel (Hill-System): C₂₃H₁₆BrF₄N₃ ·CF₃CO₂H
• CAS-Nummer: 2773428-35-4
• Molekulargewicht: 604.31
• UNSPSC-Code: 12352200

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: desiccated
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C

Beschreibung

Biochem./physiol. Wirkung

FerroLOXIN-2 is a ferroptosis inhibitor that selectively targets the 15LOX/PEBP1 catalytic complex without affecting the biosynthesis of pro-/anti-inflammatory lipid mediators. FerroLOXIN-2 prevents 0.5 μM GPX4 inhibitor RSL3-induced ferroptosis in HBE cell cultures (IC50 = 97 nM post 20h RSL3 treatment) and rescues mice from total body irradiation (TBI)-induced death in vivo (Cpd administered via 25 mg/kg ip. 20h post 9.25Gy irradiation; survival on day 30 = 80% vs. 0% on day 19 of untreated control). FerroLOXIN-2 does not exert its efficacy via radical scavenging or iron-chelating activity, nor does it prevent cell death by necroptosis, pyroptosis, or apoptosis.

Vorsicht

Hygroscopic